From: Yoga management of breast cancer-related lymphoedema: a randomised controlled pilot-trial
VAS | Group mean ± SD b-8 | Between group changes 0-8 |  | Group mean ± SD 8b-12 | Between group changes 8b-12 | ||||
---|---|---|---|---|---|---|---|---|---|
Variable Gp(n) | Week 0 M ± SD | Week 8 M ± SD | ∆int-∆con 0–8 MD; (95% CI) | P(0–8) | Variable Gp(n) | Week 8b M ± SD | Week 12 M ± SD | ∆int-∆con 8b-12 MD; (95% CI) | P(8b-12) |
Sensations | |||||||||
Con(11) | 1.97 ± 1.89 | 2.01 ± 2.15 | -0.55; (02.33 to 1.23) | 0.345†| Con(10) | 2.20 ± 2.17 | 2.20 ± 2.12 | 0.30; (-1.21 to 1.81) | 0.698 |
Int(12) | 2.39 ± 2.12 | 1.88 ± 1.83 | Int(9) | 1.96 ± 1.59 | 2.26 ± 2.29 | ||||
Pain | |||||||||
Con(11) | 1.69 ± 2.31 | 1.44 ± 2.24 | 0.06; (-0.74 to 0.87) | 0.878 | Con(10) | 1.57 ± 2.31 | 1.16 ± 1.48 | 0.81; (-0.33 to 1.95) | 0.165 |
Int(12) | 0.99 ± 1.53 | 0.80 ± 1.48 | Int(9) | 1.00 ± 1.67 | 1.40 ± 1.84 | ||||
Fatigue | |||||||||
Con(11) | 1.71 ± 2.21 | 2.06 ± 2.52 | -1.05; (-2.50 to 0.41) | 0.117†| Con(10) | 2.26 ± 2.56 | 1.57 ± 1.54 | 0.42; (-1.45 to 2.30) | 0.551†|
Int(12) | 2.58 ± 2.60 | 1.88 ± 2.23 | Int(9) | 2.37 ± 2.50 | 2.10 ± 1.77 | ||||
Sensations limit activity | |||||||||
Con(11) | 1.35 ± 2.81 | 0.93 ± 1.90 | -0.18; (-1.66 to 1.30) | 0.793†| Con(10) | 1.01 ± 1.98 | 0.8 ± 1.70 | 0.37; (-0.49 to 1.22) | 0.399 |
Int(12) | 1.43 ± 1.76 | 0.83 ± 0.74 | Int(9) | 1.20 ± 1.54 | 1.10 ± 1.54 | ||||
Pain limit activity | |||||||||
Con(11) | 0.57 ± 1.10 | 1.31 ± 2.39 | -0.99; (-2.06 to 0.09) | 0.362†| Con(10) | 1.42 ± 2.49 | 0.89 ± 1.59 | 0.72; (-0.80 to 2.24) | 0.353 |
Int(12) | 0.81 ± 1.44 | 0.56 ± 0.58 | Int(9) | 0.61 ± 0.58 | 0.80 ± 0.93 | ||||
Fatigue limit activity | |||||||||
Con(11) | 0.69 ± 1.51 | 1.34 ± 2.57 | -1.0-; (-2.44 to 0.27) | 0.315†| Con(10) | 1.46 ± 2.67 | 1.07 ± 1.74 | 0.61; (-0.78 to 2.00) | 0.389 |
Int(12) | 1.38 ± 1.85 | 0.93 ± 0.95 | Int(9) | 1.03 ± 0.95 | 1.26 ± 1.24 |